Michelle Werner

Michelle Werner joined Ipsen in March 2026 as Executive Vice President and President of North America.

Before joining Ipsen, Michelle served as CEO-Partner at Flagship Pioneering and President and CEO of Alltrna, a tRNA platform company. During her tenure at Alltrna, she built and led a team that unlocked the biology of a brand-new modality and advanced the first-ever tRNA therapeutic toward human trials. Prior to that, she served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology. Michelle has also held senior leadership positions at AstraZeneca and Bristol-Myers Squibb. Michelle started her professional career in R&D, working hands-on with patients at the Oncology Clinical Trials Unit at Harvard Medical School before moving into industry in clinical operations.  

Outside of her corporate responsibilities, Michelle is a wife and mother to three children and is a member of the rare disease community. She is serving Board appointments for the non-profit organizations Rare Disease Renegades and Cure Rare Disease, a purpose that fuels her passions both personally and professionally.

Michelle holds a B.A. in Biology and Anthropology from the University of Pennsylvania and an MBA from the London Business School.